Lesli Ivett Jimenez Garcia
Research Subjects
Lesli Ivett Jimenez Garcia has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Andres Felipe Santodomingo Galindo
Investigador independiente, Chile
1 shared publication - Armando Nolasco Toledo
Universidad Autónoma Benito Juárez de Oaxaca
1 shared publication - Erika Isabel Rogel Macas1 shared publication
- Gabriel Eduardo Dede Badillo1 shared publication
- Samira Dayuma Asquel Caiza1 shared publication
Latest Publications
- Open Access
- 5 July 2025
- Published by Sapienza Grupo Editorial in Ibero-American Journal of Health Science Research
- Vol. 5 (2) , 392-399
Tumor-infiltrating lymphocyte (TIL) therapy for immunotherapy-refractory advanced melanoma: a systematic review of response and survival rates
Advanced melanoma that progresses after immune checkpoint inhibitors (ICIs) such as anti–PD-1 and anti–CTLA-4 antibodies represents an urgent therapeutic challenge. Tumor-infiltrating lymphocyte (TIL) therapy, an adoptive cell therapy that re-infuses ex vivo–expanded autologous T cells, has shown renewed potential for overcoming immunotherapy resistance. Recent clinical trials, including lifileucel-based regimens, have reported encouraging response and survival outcomes in heavily pretreated populations. This systematic review aimed to evaluate the clinical efficacy, survival outcomes, safety, and feasibility of TIL therapy in patients with immunotherapy-refractory advanced melanoma. A comprehensive search was conducted across PubMed, Scopus, and Google Scholar for studies published between 2014 and 2025 using the terms tumor-infiltrating lymphocyte therapy, TIL therapy, advanced melanoma, and lifileucel. Eligible studies included phase I–III clinical trials, cohort studies, and systematic reviews reporting response rate (ORR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety outcomes. Across multiple phase II and III studies, lifileucel achieved objective response rates (ORRs) of 31–36% in immunotherapy-refractory cohorts, including complete responses in up to 12% of patients. The median DoR exceeded 36 months, and 31.3% of responders maintained responses at 5 years. Median PFS ranged from 4.1 to 7.2 months, and median OS from 13.9 to 25.8 months, with some patients achieving long-term disease control beyond five years. Predictors of improved response included lower tumor burden and normal LDH levels. TIL therapy exhibited a predictable and manageable safety profile, dominated by transient grade 3/4 hematologic toxicities related to lymphodepletion and IL-2. Manufacturing feasibility was high, with cryopreserved lifileucel products enabling consistent expansion and delivery across treatment centers. Continued research should refine patient selection, optimize production, and evaluate combination strategies to enhance long-term survival and broaden clinical accessibility.
- 5 July 2025
- Published by Sapienza Grupo Editorial in Ibero-American Journal of Health Science Research
- Vol. 5 (2) , 392-399
Open AccessTumor-infiltrating lymphocyte (TIL) therapy for immunotherapy-refractory advanced melanoma: a systematic review of response and survival rates
Advanced melanoma that progresses after immune checkpoint inhibitors (ICIs) such as anti–PD-1 and anti–CTLA-4 antibodies represents an urgent therapeutic challenge. Tumor-infiltrating lymphocyte (TIL) therapy, an adoptive cell therapy that re-infuses ex vivo–expanded autologous T cells, has shown renewed potential for overcoming immunotherapy resistance. Recent clinical trials, including lifileucel-based regimens, have reported encouraging response and survival outcomes in heavily pretreated populations. This systematic review aimed to evaluate the clinical efficacy, survival outcomes, safety, and feasibility of TIL therapy in patients with immunotherapy-refractory advanced melanoma. A comprehensive search was conducted across PubMed, Scopus, and Google Scholar for studies published between 2014 and 2025 using the terms tumor-infiltrating lymphocyte therapy, TIL therapy, advanced melanoma, and lifileucel. Eligible studies included phase I–III clinical trials, cohort studies, and systematic reviews reporting response rate (ORR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety outcomes. Across multiple phase II and III studies, lifileucel achieved objective response rates (ORRs) of 31–36% in immunotherapy-refractory cohorts, including complete responses in up to 12% of patients. The median DoR exceeded 36 months, and 31.3% of responders maintained responses at 5 years. Median PFS ranged from 4.1 to 7.2 months, and median OS from 13.9 to 25.8 months, with some patients achieving long-term disease control beyond five years. Predictors of improved response included lower tumor burden and normal LDH levels. TIL therapy exhibited a predictable and manageable safety profile, dominated by transient grade 3/4 hematologic toxicities related to lymphodepletion and IL-2. Manufacturing feasibility was high, with cryopreserved lifileucel products enabling consistent expansion and delivery across treatment centers. Continued research should refine patient selection, optimize production, and evaluate combination strategies to enhance long-term survival and broaden clinical accessibility.